Navigation Links
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Date:4/20/2009

tection when given within 12 hours of an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our first Phase I human safety study demonstrated that Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin. This second study will continue to expand our safety database and provide additional pharmacokinetic data."

Dr. Posillico added, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited about Anthim because the results of all of our studies show that treatment with Anthim has the potential to provide significant therapeutic benefit for people infected with anthrax in a bioterrorism emergency." Currently antibiotics represent the only therapeutic option for anthrax infection. Antibiotics target the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, antibiotic resistant strains of anthrax could be used in a bioterror attack, making the medical need for anti-toxin therapy even more acute.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. The National Institutes of Health and the Department of Defense have awarded Elusys a total of $34 million for the development of Anthim, of which $12 million was awarded in September 2007 under contract #HHSN272200700035 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Hea
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Another LNA-based RNA Inhibitor Enters Clinical Trials
7. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
8. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
(Date:9/19/2014)... , Sept. 19, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today that it ... registered shares of common stock and 3,605,042 unregistered ... purchase price for one registered share of common ... unregistered share of common stock will be $3.475.  ...
(Date:9/19/2014)... 19, 2014  Over 200 runners participated in the ... the Radiation Oncology Institute (ROI), hosted by Radiation Business ... Park in San Francisco.  "Donations are ... of Radiation Business Solutions, "but at this point, ... $70,000 for the ROI this year. This surpasses last ...
Breaking Medicine Technology:CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... NEW YORK, Jan. 13, 2011 Reportlinker.com announces ... in its catalogue: Teva Pharma. ... http://www.reportlinker.com/p0360241/Teva-Pharma-Industries-Ltd-PharmaVitae-Profile.html Introduction ... performance for Teva in the prescription pharmaceutical sector. ...
... 13, 2011 Reportlinker.com announces that a new market ... UCB S.A.: PharmaVitae Profile ... This analysis examines the historical and forecast performance ... encompasses global company strategy, portfolio and pipeline analysis and ...
Cached Medicine Technology:Reportlinker Adds Teva Pharma. Industries Ltd: PharmaVitae Profile 2Reportlinker Adds UCB S.A.: PharmaVitae Profile 2
(Date:9/19/2014)... 2014 Are you tired of having ... with seasonal allergies or sinus congestion? Fortunately, an inventor ... , She conceived of Nose Pal to avoid ... nose in public. Since it prevents nasal drip and ... conditions, particularly when cooking or working closely with others. ...
(Date:9/19/2014)... (HealthDay News) -- As kids transition from elementary to ... according to a recent study. But the ... found that verbal and physical bullying declines as students ... and prevention strategies must address all types of bullying ... girls, the researchers said. The study was published recently ...
(Date:9/19/2014)... Phoenix, AZ (PRWEB) September 19, 2014 Hastings ... over 30 years in the industry, announces a record number ... firm handles a wide variety of serious injury cases as ... cases along with dog bite related accident cases and others. ... Hastings and Hastings has stood the test of time when ...
(Date:9/19/2014)... According to a report from HarrisMartin ... Xarelto, named as defendants in several lawsuits filed in ... the court to dismiss those suits because the alleged ... with Philadelphia.* The cases include, for instance, Fontan v. ... Comm. Pls., Philadelphia Cty.), which was brought by a ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Your brain structure could help predict ... study suggests. Researchers at Yale University found those with ... the parietal cortex may be more likely to engage in ... , , The study, funded by the U.S. National Institute ... women living in the Northeast. The researchers sought to determine ...
Breaking Medicine News(10 mins):Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2
... Wants Consumers to Go Back to the Basics: Healthy Living ... Chance to Win a Luxury Resort & Spa ExperienceWESTCHESTER, Ill., ... people who make New Year,s resolutions fall off the wagon ... we give ourselves such lofty expectations in the first place? ...
... NEW YORK, March 5 HMS Holdings Corp. ... for government healthcare programs, today announced the promotions ... Christina Dragonetti to Executive Vice President, Commercial Markets; ... Markets. These promotions follow the company,s announcement on ...
... AED industry-leading commitment to research and developmentGrand opening ... the American Academy of Dermatology (AAD)HAYWARD, Calif., March ... SLTM ) today announced the opening of the ... new product development, facilitate research on the innovative ...
... AAD Launches include New Technologies, Innovative Applications and New ... several new launches at the upcoming 67th annual meeting ... CA. Aligned with the company,s strategic imperative to stay ... launches will focus on the company reinforcing its ...
... they,re better able to play sports, be accepted by ... to glasses, contact lenses improve how children feel about ... acceptance among friends, a study of 484 nearsighted children ... spectacle wear on self-perception and the perception of others, ...
... Broadcasts of The Patient Channel and The Newborn ... Wegener Corporation (Nasdaq: WGNR ), a ... data distribution networks worldwide, today announced that the ... division of the iVillage Networks, recently upgraded its ...
Cached Medicine News:Health News:Samantha Harris Launches 'A Toast for Everyday Health' 2Health News:Samantha Harris Launches 'A Toast for Everyday Health' 3Health News:Samantha Harris Launches 'A Toast for Everyday Health' 4Health News:HMS Holdings Corp. Announces Executive Promotions 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 3Health News:Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting 2Health News:Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting 3Health News:Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting 4Health News:Contact Lenses Boost Kids' Self-Image 2Health News:NBC Digital Health Network Upgrades WEGENER(R) Compel(R) Network Control System and Adds MediaPlan(R) Content Management System 2Health News:NBC Digital Health Network Upgrades WEGENER(R) Compel(R) Network Control System and Adds MediaPlan(R) Content Management System 3Health News:NBC Digital Health Network Upgrades WEGENER(R) Compel(R) Network Control System and Adds MediaPlan(R) Content Management System 4Health News:NBC Digital Health Network Upgrades WEGENER(R) Compel(R) Network Control System and Adds MediaPlan(R) Content Management System 5
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: